Australian Centre For Vertebrate Mutation Detection (ACVMD)
Funder
National Health and Medical Research Council
Funding Amount
$1,611,794.00
Summary
Over the last 20 years, generation and analysis of genetically modified animals has proven to be an important step in the transition from in vitro studies of gene function to in vivo studies and eventually clinical research. The remarkable parallels between the human, mouse and zebrafish genomes means that there are now many examples of mutations that cause or modify disease in humans, and which lead to similar phenotypes when present in mice and zebrafish. Until recently, the prime method of in ....Over the last 20 years, generation and analysis of genetically modified animals has proven to be an important step in the transition from in vitro studies of gene function to in vivo studies and eventually clinical research. The remarkable parallels between the human, mouse and zebrafish genomes means that there are now many examples of mutations that cause or modify disease in humans, and which lead to similar phenotypes when present in mice and zebrafish. Until recently, the prime method of introducing mutations into specific genes of interest in the mouse (although still unavailable in the fish) was via homologous recombination, and the principal classes of mutations induced were large deletions or insertions. This type of mutation rarely occurs in humans. Rather, point mutations and single-nucleotide polymorphisms are the prevalent form of genetic variation. An alternative approach to the development of mouse models with the more relevant point mutations is TILLING (Targeting Induced Local Lesions IN Genomes). The goal of this Enabling Grant is to make TILLING technology accessible to the Australian research community and in doing so promote movement of research from the in vitro setting into animal models of disease.Read moreRead less
The aim of this application is to find new therapeutic strategies for genetic epilepsy. "Disease in a dish" models as well as whole animal models will be generated that contain patient gene mutations and the underlying disease processes will be characterised. Using these models a range of existing and new drugs will be tested to select those that most completely reverse these disease processes. These results will feed into clinical trials in patients with appropriate genetic profiles.
Germline Mutations In Mismatch Repair Genes: Prevalence, Risk Of Cancer, And Environmental Modifiers Of Risk.
Funder
National Health and Medical Research Council
Funding Amount
$216,750.00
Summary
Aims: 1. Develop a model that will predict who has a mutation in a group of genes that cause cancer 2. Estimate risk of cancer in people who have a mutation in these genes (carriers) 3. Determine if cancer risk in carriers can be reduced People who inherit a mutation in a group of genes called 'mismatch repair genes' are at increased risk of cancer, particularly cancer of the colon and rectum. If these carriers can be identified they can take preventive measures such as screening to reduce their ....Aims: 1. Develop a model that will predict who has a mutation in a group of genes that cause cancer 2. Estimate risk of cancer in people who have a mutation in these genes (carriers) 3. Determine if cancer risk in carriers can be reduced People who inherit a mutation in a group of genes called 'mismatch repair genes' are at increased risk of cancer, particularly cancer of the colon and rectum. If these carriers can be identified they can take preventive measures such as screening to reduce their risk of cancer and death. We will develop a model using data from the Colon Cancer Family Registry (CFR), the world's largest dataset of carriers and non-carriers which has already recruited and genetically tested over 4,000 families from Australasia, USA and Canada. The model will allow clinicians to predict who is a likely be a carrier based so they can be tested for the mutation. We know the risk of cancer is high in carriers, but we don't have precise estimates. We will use the Colon CFR applying sophisticated statistical methods required to answer this question. This data is critical for genetic counselling so appropriate decisions can be made by the patient and the doctor as to what preventive measures to take. We will also use the Colon CFR data to find out what how the carriers who develop cancer differ from those who stay cancer free using their completed lifestyle questionnaires which includes questions on diet, smoking, alcohol consumption, exercise, aspirin use, and oral contraceptive pill use. We may identify risk factors that carriers can avoid (or take up if they reduce cancer risk) to reduce their risk of cancer.Read moreRead less
The Genetic Control Of Platelet Production And Function
Funder
National Health and Medical Research Council
Funding Amount
$558,920.00
Summary
Platelets are the tiny cells that circulate in the body and make blood clot. The human body has more than a trillion of them at any one time, and they are replaced every week by the blood producing cells that reside in the bone marrow. Keeping the normal number of platelets steady is incredibly important any significant drop can result in a life-threatening hemorrhage. The clinical name given to a low platelet count is thrombocytopenia, and it is a very common problem. It can be caused by geneti ....Platelets are the tiny cells that circulate in the body and make blood clot. The human body has more than a trillion of them at any one time, and they are replaced every week by the blood producing cells that reside in the bone marrow. Keeping the normal number of platelets steady is incredibly important any significant drop can result in a life-threatening hemorrhage. The clinical name given to a low platelet count is thrombocytopenia, and it is a very common problem. It can be caused by genetic mutations, viral infections, or by cancer treatments like chemotherapy. The only way to raise platelet numbers in a person with thrombocytopenia is a blood transfusion, which carries with it risks and potential side effects. While we understand quite a lot about how the body produces platelets, we don t know anywhere enough to be able to develop new treatments. Our work is focused on the identification of the genes that control the process, beginning with mouse models of thrombocytopenia, genome mapping, gene isolation, and finally, making the links between the newly identified genes and patients with thrombocytopenia. It will give us a much better understanding of how platelets are produced, how things go wrong in human disease, and how new therapies might be developed to treat them.Read moreRead less
Hypothalamic Regulation Of Appetite And Energy Homeostasis In Prader-Willi Syndrome.
Funder
National Health and Medical Research Council
Funding Amount
$39,987.00
Summary
Prader-Willi syndrome (PWS) is a genetic disease affecting 1/~15 000 people. It causes insatiable appetite and often morbid obesity, as well as other developmental problems. It is thought that there is a defect in the way that the brain regulates eating behaviour in PWS, but the exact mechanism is still unknown. This study proposes to explore metabolic and genetic factors contributing to the appetite disorder in PWS. It will also explore new ways of treating excessive appetite.
Protein Prenylation And Inflammation: New Insights Into The Pathophysiology And Treatment Of Mevalonate Kinase Deficiency
Funder
National Health and Medical Research Council
Funding Amount
$715,755.00
Summary
This project is focused on a genetic, potentially fatal, inflammatory disease that appears in infancy. We have developed a new way of detecting the underlying defect as well as the first animal models that have the same genetic mutations and mimic the disease. With these revolutionary new approaches, we will discover the exact cause of the inflammation, test a new way of diagnosing the disease, and identify new and better therapies that treat the underlying cause rather than just the symptoms.
Modelling Epileptic Encephalopathies Using Induced Stem Cells
Funder
National Health and Medical Research Council
Funding Amount
$506,489.00
Summary
Genetics is poised to have a massive impact on how we diagnose and treat diseases. Precision medicine is a relatively new concept that has been put forward to encompass approaches to finding genetic and functional markers of a disease process so that better treatments that are specifically targeted to a specific patients pathology. Here we will explore the development of stem cells to create "disease in a dish" models for severe forms of epilepsy to be used for development of new therapies.
Inherited Muscle Disorders - Gene Discovery, Pathobiology And Therapy.
Funder
National Health and Medical Research Council
Funding Amount
$1,750,277.00
Summary
The project proposed by Professors Nigel Laing and Kathryn North and Dr Kristen Nowak is based upon the results of their successful identification of disease genes for genetic muscle diseases. The project is divided into three parts. In the first part of the project, the research team will identify further novel disease genes, some of which they are already close to finding. In the second part of the project the team will determine how the mutations they have identified in the disease genes actu ....The project proposed by Professors Nigel Laing and Kathryn North and Dr Kristen Nowak is based upon the results of their successful identification of disease genes for genetic muscle diseases. The project is divided into three parts. In the first part of the project, the research team will identify further novel disease genes, some of which they are already close to finding. In the second part of the project the team will determine how the mutations they have identified in the disease genes actually cause the diseases. The aim of this work is to discover targets that may ultimately lead to new therapies for these muscle diseases. In the third and final part of the project, the team will pursue one possible therapeutic approach, which is based upon the understanding of the diseases the researchers have gained from their previous studies. There are currently no cures for these muscle diseases, though symptoms can be treated. The team will determine whether heart actin can replace muscle actin in skeletal muscle and thus might treat the muscle disease.Read moreRead less